CellaVision AB (publ)

Welcome, everyone, and thank you for joining us today. My name is Steve Ferguson.

Welcome to Celevision Q2 Report 2026. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Steve Ferguson. Please go ahead.

Good morning, everyone, and thank you for joining us today. My name is Steve Ferguson, and with me is our Chief Financial Officer, Monika Jonsson. We appreciate you taking the time to join us this morning as we present CELAVision's results for the second quarter of 2026. Following the presentation, both Monika and I will be happy to take questions. As this is my first quarterly earnings call since joining CELAVision as CEO on June the 5th, I'd also like to take a moment just to very briefly introduce myself. Before joining Cellavision, I spent more than 25 years in international leadership roles across the life science, diagnostic and healthcare industries. Most recently, I was serving as CEO of Medics Biochemica in Finland, following senior commercial and operational leadership positions at Thermo Fisher Scientific, or Fadia, in Uppsala, and prior to that with Lundbeck, based in Saalbu in Copenhagen. I'm really super excited to be part of Cellavision. and to the challenge ahead, and I look forward to working together with our very talented team, our partners, and all of you as we continue to build on the company's strong foundation to advance laboratory workflow and diagnostic certainty through intelligent microscopy. I'm speaking to you this morning from Vancouver, where it's 2 a.m., so I'll do my best to keep our energy high during this call. So with that, please let's turn to our second quarter results. So Cellavision's second quarter represents a solid performance and recovery from the slower start to the year. The quarter resulted in net sales of 200 million sec, an increase of 4.5% over quarter two, 2025. Sales increased organically by 5.6%, where we saw a 1.1% headwind on currency. And EBITDA for the period amounted to 55 million SEK, which corresponds to 27% EBITDA margin. EBITDA for the second quarter was charged with expenses of 9 million SEK associated with the initial costs of the CEO transition. adjusted for these expenses, EBITDA increased compared to the same quarter last year. As we highlight in the report, Americas reached an all-time high sales, fueled by large instruments, and this was driven by the accelerated workflow uptake among mid-size and large laboratory networks. EMEA showed a stable result, but was still slightly affected by the now concluded inventory adjustment from our main distributor partner. And finally, in APAC, we maintained a steady development, though market conditions remain challenging, particularly in China. We see a notable uptake of the reagents business in both Japan and Australia, along with a tender win for the UN, the United Nations. The commercial launch of our bone marrow aspirate application, or VMA, in EMEA marks an important milestone in our expansion into specialized microscopy. Initial customer interest and sales have been encouraging, reinforcing our confidence in this market opportunity and demonstrating our ability to translate our innovation and our R&D investments into commercial results. We continue to progress outside of Europe with the FDA registration process for bone marrow with our aim of obtaining a 510 clearance in the US before year end. And finally, the development of the FPM technology continues to progress through our development phases, forming the foundation of our next generation haematology analyzers, and this strengthens our confidence in FPM as a platform technology for future innovation beyond haematology. These are exciting developments for Cellavision. And right now, let me hand over to Monica to present an overview of the financial development during quarter two, 2026.